FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2567216998> ?p ?o ?g. }

• W2567216998 abstract "Abstract The proteasome inhibitor bortezomib (BTZ, PS-341, Velcade®) has proven to be an effective drug in the treatment of multiple myeloma (MM) patients, both in first line as in refractory disease. However, emergence of drug resistance, for which the molecular mechanism(s) remain elusive, can hamper its clinical efficacy. Recently, we showed (Oerlemans & Franke, Blood 2008) that resistance to BTZ in human THP1 acute myeloid leukemia cells was conferred by an acquired mutation in the PSMB5 gene. This mutation introduced an amino acid substitution in the highly conserved substrate binding pocket of the β5 subunit of the proteasome, which is the primary target of BTZ. In the present study we investigated whether chronic exposure to BTZ could provoke acquired resistance to BTZ in the human RPMI-8226 MM cell line model and whether a PSMB5 gene mutation would be responsible. To this end, 8226 cells were exposed in vitro to stepwise increasing concentrations of BTZ from 0.1 nM BTZ up to 7nM (8226/BTZ7) over a period of 6 months and up to 30nM (8226/BTZ30) over a period of 12 months. In parallel to these selective concentrations, RPMI-8226 cells were cultured without BTZ (8226/WT). Characterization of 8226/BTZ7 vs 8226/WT cells revealed: 2.6-fold resistance to BTZ along with cross-resistance to other peptide-based proteasome inhibitors; MG132 (2.2-fold), MG262 (1.9-fold) and 4A6 (4.9 fold), unchanged sensitivity to other anti-MM drugs, including doxorubicin, melphalan and thalidomide, a marked gain in sensitivity for the glucocorticoids dexamethasone (IC50: 25 nM vs &gt;10 uM, respectively) and prednisolone (IC50: 2 uM vs &gt; 1000 uM, respectively), other than 8226/WT cells, no G2M cell cycle arrest after BTZ exposure in 8226/BTZ7 cells, no significant changes in mRNA and functional activity of the three dominant catalytic subunits of the proteasome; β1, β2 and β5, although at a protein level β5 expression was markedly increased (5–10 fold), and sequencing of the PSMB5 gene in 8226/BTZ7 and 8226/BTZ30 cells, and one clinical sample of plasma cells of a BTZ-resistant plasma cell leukemia patient, showed no evidence for PSMB5 mutations. Microarray experiments were initiated to further elicit possible molecular mechanism(s) of BTZ resistance in 8226/BTZ7 cells. Initial analysis showed upregulation of several genes involved in microenvironment interaction and plasma cell differentiation. In this context, Gene Set Enrichment Analysis (GSEA) showed enrichment in the 8226/BTZ7 for the gene sets related to CD138 upregulation and MYC upregulation, indicative for a more differentiated phenotype of 8226/BTZ7 cells. Consistently, immune phenotypic characterization showed a shift to a dominant CD138dim/CD45+/CD20dim/CD27dim cell population for 8226/WT cells grown in parallel with 8226/BTZ7, which retained a CD138+/CD45−/CD20−/CD27− marker profile. Collectively, these data indicate that, other than in acute leukemia, the onset of acquired resistance to BTZ in 8226 MM cells proceeds very slowly, is associated with the upregulation of a (non-mutated) β5 catalytic proteasome subunit, and goes along with a shift towards a more mature immune phenotype in combination with an enrichment of genes that support cell growth. Notwithstanding this fact, the marked sensitization of BTZ-resistant 8226 MM cells for glucocorticoids may further corroborate the use of these drugs in combination with BTZ." @default.
• W2567216998 created "2017-01-06" @default.
• W2567216998 creator A5007946879 @default.
• W2567216998 creator A5008363132 @default.
• W2567216998 creator A5015512839 @default.
• W2567216998 creator A5032118562 @default.
• W2567216998 creator A5033467261 @default.
• W2567216998 creator A5034988854 @default.
• W2567216998 creator A5062392239 @default.
• W2567216998 creator A5067029743 @default.
• W2567216998 creator A5070729528 @default.
• W2567216998 creator A5074556930 @default.
• W2567216998 creator A5083385949 @default.
• W2567216998 date "2008-11-16" @default.
• W2567216998 modified "2023-09-27" @default.
• W2567216998 title "Acquired Resistance to Bortezomib in Human RPMI-8226 Multiple Myeloma Cells: Molecular Characterization, Cross-Resistance with Other Proteasome Inhibitors but Marked Sensitization to Glucocorticoids" @default.
• W2567216998 doi "https://doi.org/10.1182/blood.v112.11.2640.2640" @default.
• W2567216998 hasPublicationYear "2008" @default.
• W2567216998 type Work @default.
• W2567216998 sameAs 2567216998 @default.
• W2567216998 citedByCount "0" @default.
• W2567216998 crossrefType "journal-article" @default.
• W2567216998 hasAuthorship W2567216998A5007946879 @default.
• W2567216998 hasAuthorship W2567216998A5008363132 @default.
• W2567216998 hasAuthorship W2567216998A5015512839 @default.
• W2567216998 hasAuthorship W2567216998A5032118562 @default.
• W2567216998 hasAuthorship W2567216998A5033467261 @default.
• W2567216998 hasAuthorship W2567216998A5034988854 @default.
• W2567216998 hasAuthorship W2567216998A5062392239 @default.
• W2567216998 hasAuthorship W2567216998A5067029743 @default.
• W2567216998 hasAuthorship W2567216998A5070729528 @default.
• W2567216998 hasAuthorship W2567216998A5074556930 @default.
• W2567216998 hasAuthorship W2567216998A5083385949 @default.
• W2567216998 hasConcept C203014093 @default.
• W2567216998 hasConcept C27740335 @default.
• W2567216998 hasConcept C2776364478 @default.
• W2567216998 hasConcept C2777478702 @default.
• W2567216998 hasConcept C2778367456 @default.
• W2567216998 hasConcept C502942594 @default.
• W2567216998 hasConcept C55493867 @default.
• W2567216998 hasConcept C71924100 @default.
• W2567216998 hasConcept C86803240 @default.
• W2567216998 hasConcept C98274493 @default.
• W2567216998 hasConceptScore W2567216998C203014093 @default.
• W2567216998 hasConceptScore W2567216998C27740335 @default.
• W2567216998 hasConceptScore W2567216998C2776364478 @default.
• W2567216998 hasConceptScore W2567216998C2777478702 @default.
• W2567216998 hasConceptScore W2567216998C2778367456 @default.
• W2567216998 hasConceptScore W2567216998C502942594 @default.
• W2567216998 hasConceptScore W2567216998C55493867 @default.
• W2567216998 hasConceptScore W2567216998C71924100 @default.
• W2567216998 hasConceptScore W2567216998C86803240 @default.
• W2567216998 hasConceptScore W2567216998C98274493 @default.
• W2567216998 hasLocation W25672169981 @default.
• W2567216998 hasOpenAccess W2567216998 @default.
• W2567216998 hasPrimaryLocation W25672169981 @default.
• W2567216998 hasRelatedWork W1971207361 @default.
• W2567216998 hasRelatedWork W2088060877 @default.
• W2567216998 hasRelatedWork W2511036762 @default.
• W2567216998 hasRelatedWork W2529420833 @default.
• W2567216998 hasRelatedWork W2551541272 @default.
• W2567216998 hasRelatedWork W2554097210 @default.
• W2567216998 hasRelatedWork W2556241839 @default.
• W2567216998 hasRelatedWork W2573160903 @default.
• W2567216998 hasRelatedWork W2585382861 @default.
• W2567216998 hasRelatedWork W2586586516 @default.
• W2567216998 hasRelatedWork W2591532479 @default.
• W2567216998 hasRelatedWork W2625038023 @default.
• W2567216998 hasRelatedWork W2894951270 @default.
• W2567216998 hasRelatedWork W2986312716 @default.
• W2567216998 hasRelatedWork W2988165302 @default.
• W2567216998 hasRelatedWork W3002758256 @default.
• W2567216998 hasRelatedWork W3010419395 @default.
• W2567216998 hasRelatedWork W3025333682 @default.
• W2567216998 hasRelatedWork W3136935594 @default.
• W2567216998 hasRelatedWork W995647036 @default.
• W2567216998 isParatext "false" @default.
• W2567216998 isRetracted "false" @default.
• W2567216998 magId "2567216998" @default.
• W2567216998 workType "article" @default.